Ligand Competitors
| LGND Stock | USD 192.10 3.07 1.57% |
Ligand Pharmaceuticals vs NewAmsterdam Pharma Correlation
Weak diversification
The correlation between Ligand Pharmaceuticals Incorpo and NAMS is 0.34 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ligand Pharmaceuticals Incorpo and NAMS in the same portfolio, assuming nothing else is changed.
Moving against Ligand Stock
As of January 31, 2026, Return On Tangible Assets is expected to decline to -0.0067. In addition to that, Return On Capital Employed is expected to decline to -0.02. At present, Ligand Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 191.4 M, whereas Total Current Assets are forecasted to decline to about 222 M.Ligand Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ligand Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Ligand and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ligand Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Ligand Stock performing well and Ligand Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ligand Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PRAX | 4.14 | 0.95 | 0.22 | 4.90 | 3.90 | 9.33 | 36.21 | |||
| BLTE | 2.85 | 1.00 | 0.28 | (1.04) | 2.65 | 7.96 | 18.84 | |||
| MIRM | 1.96 | 0.56 | 0.26 | 1.21 | 1.70 | 4.60 | 13.83 | |||
| ACAD | 1.61 | 0.11 | 0.07 | 0.14 | 1.51 | 3.31 | 9.79 | |||
| ADMA | 2.22 | 0.13 | 0.06 | 0.12 | 2.62 | 5.01 | 13.78 | |||
| SLNO | 2.85 | (0.63) | 0.00 | (0.50) | 0.00 | 5.19 | 31.78 | |||
| VKTX | 2.69 | (0.31) | 0.00 | (0.20) | 0.00 | 7.49 | 19.06 | |||
| CRNX | 2.26 | 0.38 | 0.14 | 0.63 | 2.29 | 4.38 | 19.30 | |||
| DYN | 3.94 | 0.27 | 0.05 | (3.26) | 4.71 | 7.01 | 58.12 | |||
| NAMS | 2.40 | (0.21) | 0.00 | (0.28) | 0.00 | 4.72 | 15.37 |
Cross Equities Net Income Analysis
Compare Ligand Pharmaceuticals and related stocks such as Praxis Precision Med, Belite Bio ADR, and Mirum Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRAX | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (35.5 M) | (61.8 M) | (166.9 M) | (213.1 M) | (123.3 M) | (182.8 M) | (164.5 M) | (172.8 M) |
| BLTE | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (9.7 M) | (12.6 M) | (31.6 M) | (36.1 M) | (32.5 M) | (30.9 M) |
| MIRM | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (52.6 M) | (103.3 M) | (84 M) | (135.7 M) | (163.4 M) | (87.9 M) | (79.1 M) | (83.1 M) |
| ACAD | (10.2 M) | (22.8 M) | (20.8 M) | (37.9 M) | (92.5 M) | (164.4 M) | (271.4 M) | (289.4 M) | (245.2 M) | (235.3 M) | (281.6 M) | (167.9 M) | (216 M) | (61.3 M) | 226.5 M | 203.8 M | 214 M |
| ADMA | (29.7 M) | (26.5 K) | (7.3 M) | (15.5 M) | (16.8 M) | (18 M) | (19.5 M) | (43.8 M) | (65.7 M) | (48.3 M) | (75.7 M) | (71.6 M) | (65.9 M) | (28.2 M) | 197.7 M | 227.3 M | 238.7 M |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| VKTX | (444) | (444) | (444) | (146.2 K) | (21.9 M) | (23.4 M) | (14.7 M) | (20.6 M) | (22.1 M) | (25.8 M) | (39.5 M) | (55 M) | (68.9 M) | (85.9 M) | (110 M) | (99 M) | (94 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.2 M) | (27.1 M) | (49.5 M) | (72.9 M) | (106.7 M) | (160 M) | (214.5 M) | (298.4 M) | (268.6 M) | (255.1 M) |
| DYN | 264 M | (1.6 B) | 87 M | (356 M) | (67 M) | 50 M | (1.2 B) | 76 M | (4.8 M) | (13.5 M) | (58.7 M) | (149.3 M) | (165.2 M) | (235.9 M) | (317.4 M) | (365 M) | (383.3 M) |
| NAMS | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (41.8 M) | (22.6 M) | (176.9 M) | (241.6 M) | (217.4 M) | (206.6 M) |
Ligand Pharmaceuticals and related stocks such as Praxis Precision Med, Belite Bio ADR, and Mirum Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Ligand Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Ligand Pharmaceuticals Incorporated operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Ligand Pharmaceuticals Competitive Analysis
The better you understand Ligand Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ligand Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ligand Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Ligand Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Ligand Pharmaceuticals Competition
Ligand Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ligand Pharmaceuticals in relation to its competition. Ligand Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Ligand Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ligand Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ligand Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Ligand Pharmaceuticals position
In addition to having Ligand Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Sovereign ETFs Thematic Idea Now
Broad Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Sovereign ETFs theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ligand Pharmaceuticals Correlation with its peers. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Will Biotechnology sector continue expanding? Could Ligand diversify its offerings? Factors like these will boost the valuation of Ligand Pharmaceuticals. Expected growth trajectory for Ligand significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ligand Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.032 | Earnings Share 2.27 | Revenue Per Share | Quarterly Revenue Growth 1.228 | Return On Assets |
Understanding Ligand Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Ligand's accounting equity. The concept of intrinsic value—what Ligand Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ligand Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Ligand Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ligand Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ligand Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.